Cookies on this site

Oxford Cancer is delighted to announce the appointment of Professor Adam Mead as Director, joining Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

The expanded leadership team brings together internationally recognised expertise spanning clinical trials, immuno-oncology, translational science, and fundamental research, reflecting Oxford Cancer’s commitment to accelerating innovation from discovery science to patient benefit. 

Professor Adam Mead is Professor of Haematology at the University of Oxford, Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust, and Deputy Director of the MRC Weatherall Institute of Molecular Medicine based at the Radcliffe Department of Medicine. His research focuses on understanding the genetic and cellular complexity of myeloproliferative neoplasms and related blood cancers, with the aim of developing more precise and effective treatments for patients.   

An internationally recognised clinician scientist, Professor Mead has led pioneering translational research programmes combining stem cell biology, genomics, and clinical trials to better understand how blood cancers develop, evolve, and respond to treatment. His appointment further strengthens Oxford Cancer’s breadth across solid tumour and haematological cancer research. 

Professor Mead said: 

“I am delighted to join Mark and Tim in leading Oxford Cancer at such an exciting time for cancer research in Oxford. The strength of collaboration across the University, our NHS partners, and industry creates enormous opportunities to accelerate progress for patients. I look forward to working with colleagues across disciplines to support innovation and strengthen our cancer research community.” 

Professor Mark Middleton said: 

“Adam is an outstanding clinician scientist whose work exemplifies Oxford’s strengths in translational cancer research. His appointment broadens our leadership across cancer disciplines and strengthens our ability to connect discovery science with clinical impact.” 

Professor Tim Elliott added: 

“Oxford Cancer’s success depends on bringing together expertise from across different fields of cancer research. Adam’s leadership and internationally recognised work has impact across multiple disciplines and will be an enormous asset as we continue to build a collaborative and ambitious research environment.” 

Similar stories

OCION 2024 Funding Scheme is live!

The 2024 Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is now open!

Oxford Cancer: 5 minutes with Professor Dame Molly Stevens

Professor Dame Molly Stevens is John Black Professor of Bionanoscience in the Department of Physiology, Anatomy and Genetics and the Institute of Biomedical Engineering. She recently moved her lab from Imperial College London to the University of Oxford and the Kavli Institute for nanoscience discovery, and she is joining the Oxford Cancer community.

Key exosome subtype in cancer progression identified

Collaborative work from the Department of Physiology, Anatomy and Genetics and the Department of Oncology has revealed a potential new pathway to block the production of a specific group of exosomes made in the cell’s recycling system that can promote the growth of cancerous tumours.